EGFR/EGFRvIII Dual-Targeting Peptide-Mediated Drug Delivery for Enhanced Glioma Therapy
Authors:
- 17 July 2017
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 9 (29) , 24462-24475
Abstract
Tumor-homing peptides have been widely used to mediate active targeted drug delivery. l-AE is a reported targeting peptide demonstrating high binding affinity to epidermal growth factor receptor (EGFR) and mutation variant III (EGFRvIII) overexpressed on neovasculature, vasculogenic mimicry, tumor cells, and tumor stem cells. To improve its proteolytic stability, a d-peptide ligand (termed d-AE, the enantiomer of l-AE) was developed. d-AE was confirmed to bind receptors EGFR and EGFRvIII with targeting capability comparable to l-AE. In vivo biodistribution demonstrated the superiority of d-AE in prolonged circulation and enhanced intratumoral accumulation. Furthermore, stabilized peptide modification endowed micelles higher transcytosis efficiency and penetrating capability on blood–brain tumor barrier/U87 tumor spheroids coculture model. When paclitaxel (PTX) was loaded, d-AE-micelle/PTX demonstrated excellent antitumor effect in comparison to Taxol, micelle/PTX, and l-AE-micelle/PTX. These findings indicated that the multitargeted drug delivery system enabled by d-AE ligand provides a promising way for glioma therapy.Keywords
Funding Information
- Ministry of Science and Technology of the People's Republic of China (2013CB932500)
- National Natural Science Foundation of China (81473149, 81690263)
- Shanghai Peak Disciplines-Integrative Medicine (20150407)
- Shanghai International Science and Technology Cooperation Fund (16430723800)
This publication has 61 references indexed in Scilit:
- Enhanced Antiglioblastoma Efficacy of Neovasculature and Glioma Cells Dual Targeted NanoparticlesMolecular Pharmaceutics, 2016
- Multi-targeting NGR-modified liposomes recognizing glioma tumor cells and vasculogenic mimicry for improving anti-glioma therapyOncotarget, 2016
- Tumor microenvironment for cancer stem cellsAdvanced Drug Delivery Reviews, 2016
- Overcoming the blood–brain tumor barrier for effective glioblastoma treatmentDrug Resistance Updates, 2015
- Blood Brain Barrier: A Challenge for Effectual Therapy of Brain TumorsBioMed Research International, 2015
- Cancer stem cell definitions and terminology: the devil is in the detailsNature Reviews Cancer, 2012
- The Blood-Brain/Tumor Barriers: Challenges and Chances for Malignant Gliomas Targeted Drug DeliveryCurrent Pharmaceutical Biotechnology, 2012
- Cancer Stem Cells: Impact, Heterogeneity, and UncertaintyCancer Cell, 2012
- Targeting the tumour vasculature: insights from physiological angiogenesisNature Reviews Cancer, 2010
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005